The Filing Desk

Arrowhead Pharmaceuticals vs Twist Bioscience

Arrowhead Pharmaceuticals ARWR · Twist Bioscience TWST · Biotechnology

Arrowhead Pharmaceuticals reported revenue of $451 million in fiscal 2026, 1.2 times Twist Bioscience's $377 million in fiscal 2025. Arrowhead Pharmaceuticals' revenue fell 45.6% in its latest year, and Twist Bioscience's grew 20.3%. Arrowhead Pharmaceuticals had an operating margin of -156.9%, against -36.2% at Twist Bioscience. Free cash flow was −$284 million at Arrowhead Pharmaceuticals and −$76 million at Twist Bioscience.

Side by side

Arrowhead PharmaceuticalsTwist Bioscience
Latest fiscal yearFY2026, Sep 30, 2026FY2025, Sep 30, 2025
Revenue$451M$377M
Revenue growth−45.6%20.3%
Revenue growth a year, last 5 years26.7%33.1%
Gross margin—50.7%
Operating margin−156.9%−36.2%
Net margin−160.6%−20.6%
Free cash flow−$284M−$76M
Free cash flow margin−63.0%−20.1%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count5.9%3.1%
Last close$47.78$111.60
P/E at the last close——
Insider trades, last 12 monthssold $37.3 millionsold $126.1 million
Piotroski F-score2 of 8—
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Arrowhead PharmaceuticalsTwist Bioscience
Operating margin
Percent of revenue
Arrowhead PharmaceuticalsTwist Bioscience
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Arrowhead PharmaceuticalsTwist Bioscience

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Arrowhead Pharmaceuticals and Twist Bioscience pages.